Cancer Biology and Molecular Therapeutics
癌症生物学和分子治疗
基本信息
- 批准号:7921845
- 负责人:
- 金额:$ 10.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-01 至 2011-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): This application requests continued support for a training program in Cancer Biology and Molecular Therapeutics that was begun in 1990. The program trains predoctoral and postdoctoral fellows in the fundamentals of cancer research by participation in didactic courses, seminars, discussion groups and performance of laboratory-based research. The training program is integrated into the research programs of the Morris Cotton Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, thereby enhancing exposure to many facets of the disease. This is a multidisciplinary program drawing together 20 faculty with appointments in 7 different academic programs. The faculty have recently been brought together in a new Cancer Biology graduate program under an umbrella Program in Experimental and Molecular Medicine (PEMM). Predoctoral students are enrolled in the PEMM program in year 1 and then select one of five themes in which they undertake their thesis research, journal clubs and seminars. Students who select Cancer Biology then become the responsibility of the Cancer Biology Graduate Program for the remainder of their training. Required didactic work includes courses in Cancer Biology, Oncogenomics, and the Ethical Conduct of Research. Currently there are 43 PhD or MD/PhD students in the laboratories of the training faculty. Students are recruited to the Training Grant after they have completed one or more years in the graduate program, and have selected a faculty mentor. This allows their performance in first year classes and research rotations to be used as evidence of their potential to succeed in the PhD program. Postdoctoral trainees are engaged in fulltime research under the mentorship of a faculty adviser, but have their research experience broadened by regular interactions with other faculty and fellows through conferences, seminars and programmatic activities. There are currently 30 postdoctoral trainees in the laboratories of the faculty. Training grant funds are used to facilitate recruitment of postdoctoral trainees, who then are encouraged to obtain alternate extramural funding, thereby enhancing the ability of the program to recruit additional trainees. This mechanism also facilitates the recruitment of minority applicants as there is a more frequent turnover of positions, and hence funds can be assigned to any qualified minority as soon as identified. This training program has had an outstanding record of achievement since its inception, and this will be further strengthened by the focused training under the new Cancer Biology Graduate Program. This new direction for the program was achieved in major part by the established track record of this training program, and as a consequence we are requesting continued support at the current level of training positions.
描述(由申请人提供):本申请要求继续支持 1990 年开始的癌症生物学和分子治疗培训计划。该计划通过参加教学课程、研讨会和讨论,对博士前和博士后研究员进行癌症研究基础知识的培训实验室研究的小组和表现。该培训计划被纳入莫里斯科顿癌症中心(美国国家癌症研究所指定的综合癌症中心)的研究计划中,从而增强了对该疾病许多方面的了解。这是一个多学科项目,汇集了 20 名教员,他们被任命为 7 个不同的学术项目。最近,该学院的教师们在实验和分子医学 (PEMM) 项目下聚集了一个新的癌症生物学研究生项目。博士前学生在第一年注册 PEMM 项目,然后选择五个主题之一进行论文研究、期刊俱乐部和研讨会。选择癌症生物学的学生将负责癌症生物学研究生项目的剩余培训。所需的教学工作包括癌症生物学、肿瘤基因组学和研究道德行为课程。目前培训教师实验室有博士生或博士生43人。学生在完成一年或多年的研究生课程并选择一名教师导师后,将获得培训补助金。这使得他们在第一年课程和研究轮换中的表现可以作为他们在博士课程中取得成功的潜力的证据。博士后学员在教师顾问的指导下从事全职研究,但通过会议、研讨会和项目活动与其他教师和研究员定期互动,拓宽了他们的研究经验。学院实验室现有博士后30名。培训补助资金用于促进博士后实习生的招募,然后鼓励他们获得替代的校外资助,从而增强该计划招募更多实习生的能力。这一机制也有利于少数族裔申请者的招聘,因为职位流动更加频繁,因此一旦确定合格的少数族裔,就可以将资金分配给任何合格的少数族裔。该培训计划自启动以来取得了优异的成绩,新的癌症生物学研究生计划下的重点培训将进一步加强这一成果。该计划的这一新方向主要是通过该培训计划的既定记录实现的,因此,我们要求在当前的培训职位水平上继续提供支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALAN R EASTMAN其他文献
ALAN R EASTMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALAN R EASTMAN', 18)}}的其他基金
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
- 批准号:
7483072 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
- 批准号:
8633002 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
- 批准号:
7629019 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
- 批准号:
9036264 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
- 批准号:
7257577 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
- 批准号:
7864084 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
- 批准号:
8499599 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
- 批准号:
9243917 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
- 批准号:
8074512 - 财政年份:2007
- 资助金额:
$ 10.2万 - 项目类别:
相似国自然基金
超声与ROS双重响应性携氧相变分子探针靶向治疗心梗后心室重构及机制研究
- 批准号:82302219
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于亲和超滤高效筛选苗药榜看雾中治疗类风湿性关节炎的小分子TNF-α抑制剂
- 批准号:82360834
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
基于自噬-NLRP3炎症小体交互调节反馈回路介导黏膜免疫与炎症双稳态解析黄芪建中汤治疗Hp相关性胃溃疡的分子机制
- 批准号:82374429
- 批准年份:2023
- 资助金额:45 万元
- 项目类别:面上项目
基于伏邪理论探讨清肠温中方通过LepR/HIF-1α信号调控组织驻留记忆CD4+T细胞代谢重编程治疗溃疡性结肠炎的分子机制
- 批准号:82374411
- 批准年份:2023
- 资助金额:45 万元
- 项目类别:面上项目
基于“益火消阴”理论四神丸调控Mst1/Drp1信号重塑记忆性Treg线粒体代谢治疗脾肾阳虚型溃疡性结肠炎的分子机制研究
- 批准号:82360871
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
相似海外基金
Phase Ib/II study of safety and efficacy of EZH2 inhibitor, tazemetostat, and PD-1 blockade for treatment of advanced non-small cell lung cancer
EZH2 抑制剂、他泽美司他和 PD-1 阻断治疗晚期非小细胞肺癌的安全性和有效性的 Ib/II 期研究
- 批准号:
10481965 - 财政年份:2024
- 资助金额:
$ 10.2万 - 项目类别:
Glut1+ cancer associated fibroblasts enforce a metabolic barrier to tumor T cell infiltration
Glut1癌症相关成纤维细胞增强了肿瘤T细胞浸润的代谢屏障
- 批准号:
10752508 - 财政年份:2024
- 资助金额:
$ 10.2万 - 项目类别:
Oral pathogen - mediated pro-tumorigenic transformation through disruption of an Adherens Junction - associated RNAi machinery
通过破坏粘附连接相关的 RNAi 机制,口腔病原体介导促肿瘤转化
- 批准号:
10752248 - 财政年份:2024
- 资助金额:
$ 10.2万 - 项目类别:
HERV proteogenomics of narcotic-driven HIV latency
麻醉药驱动的 HIV 潜伏期的 HERV 蛋白质基因组学
- 批准号:
10675341 - 财政年份:2023
- 资助金额:
$ 10.2万 - 项目类别:
Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy
选择性剪接的细胞表面蛋白作为白血病发生的驱动因素和免疫治疗的靶点
- 批准号:
10648346 - 财政年份:2023
- 资助金额:
$ 10.2万 - 项目类别: